Emerging Treatments | Obesity and Metabolic Disorders

Obesity and related metabolic disorders are at the forefront of a medical transformation—fueled by advances in therapeutic agents, novel targets, and evolving care strategies. This panel builds on prior discussions to examine the next wave of breakthroughs shaping the field that extend beyond the current GLP-1s, such as amylin agonists, and other orthogonal mechanisms in development. Experts will explore progress in single-agent and multi-target therapies, structure-function insights, the latest clinical data, and challenges in side effect management and reimbursement. This session will map the future of care—where science, policy, and patient experience converge.

Moderator

Tim Anderson, MD,

Pharmaceutical Analyst, BofA Securities

Speakers

Caroline Apovian, MD

Co-Director, Center for Weight Management and Wellness, Brigham and Women's Hospital;

Professor of Medicine, Harvard Medical School

Mehmet Furkan Burak, MD,

Endocrinologist, Brigham and Women’s Hospital;

Instructor in Medicine, Harvard Medical School

Steven Grinspoon, MD

Chief, Metabolism Unit, Massachusetts General Hospital;

Professor of Medicine, Harvard Medical School

Melanie Haines, MD,

Associate Physician, Neuroendocrine Unit, Massachusetts General Hospital;

Assistant Professor of Medicine, Harvard Medical School